The Effect of Imiquimod on Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Malignant Melanoma Cell Invasion

키워드

참고문헌 (44)

1. van Meurs T, "Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream", Dermatol Surg, 33, pp.623~626 (2007)
2. Wolf IH, "Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod", Arch Dermatol, 141, pp.510~514 (2005)
3. Naylor MF, "Treatment of lentigo maligna with topical imiquimod", Br J Dermatol, 149(Suppl 66), pp.66~70 (2003)
4. Cotter MA, "Treatment of lentigo maligna with imiquimod before staged excision", Dermatol Surg, 34, pp.147~151 (2008)
5. Woodmansee CS, "Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod", Dermatol Surg, 35, pp.1286~1289 (2009)
6. Hofmann UB, "Matrix metalloproteinases in human melanoma", J Invest Dermatol, 115, pp.337~344 (2000)
7. Hesling C, "In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases", Br J Dermatol, 150, pp.761~767 (2004)
8. Hemmi H, "Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway", Nat Immunol, 3, pp.196~200 (2002)
9. Schön M, "Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod", J Natl Cancer Inst, 95, pp.1138~1149 (2003)
10. Stockfleth E, "The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma : an overview", Br J Dermatol, 149(Suppl 66), pp.53~56 (2003)
11. Schön MP, "Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod", J Invest Dermatol, 122, pp.1266~1276 (2004)
12. Felding-Habermann B, "Integrin adhesion receptors in tumor metastasis", Clin Exp Metastasis, 20, pp.203~213 (2003)
13. Liotta LA, "Biochemical interactions of tumor cells with the basement membrane", Annu Rev Biochem, 55, pp.1037~1057 (1986)
14. Brinckerhoff CE, "Matrix metalloproteinases: a tail of a frog that became a prince", Nat Rev Mol Cell Biol, 3, pp.207~214 (2002)
15. Sun J, "Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells", J Signal Transduct, 2010, pp.985132~ (2010)
16. Gokaslan ZL, "Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors", Clin Exp Metastasis, 16, pp.721~728 (1998)
17. Kessenbrock K, "Matrix metalloproteinases:regulators of the tumor microenvironment", Cell, 141, pp.52~67 (2010)
18. Visse R, "Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry", Circ Res, 92, pp.827~839 (2003)
19. Gomez DE, "Tissue inhibitors of metalloproteinases: structure, regulation and biological functions", Eur J Cell Biol, 74, pp.111~122 (1997)
20. Brew K, "Tissue inhibitors of metalloproteinases: evolution, structure and function", Biochim Biophys Acta, 1477, pp.267~283 (2000)
21. Stetler-Stevenson WG, "TIMP-2: an endogenous inhibitor of angiogenesis", Trends Mol Med, 11, pp.97~103 (2005)
22. Stetler-Stevenson WG, "Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis", FASEB J, 7, pp.1434~1441 (1993)
23. Hofmann UB, "Role of matrix metalloproteinases in melanoma cell invasion", Biochimie, 87, pp.307~314 (2005)
24. Liotta LA, "Metastatic potential correlates with enzymatic degradation of basement membrane collagen", Nature, 284, pp.67~68 (1980)
25. Strongin AY, "Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease", J Biol Chem, 270, pp.5331~5338 (1995)
26. Väisänen A, "Matrix metalloproteinase-2 (72 kD type IV collagenase)expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value", J Pathol, 180, pp.283~289 (1996)
27. Väisänen A, "Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma", J Pathol, 186, pp.51~58 (1998)
28. Pyke C, "Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer", Am J Pathol, 142, pp.359~365 (1993)
29. Sakata K, "Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary", Int J Oncol, 17, pp.673~681 (2000)
30. van den Oord JJ, "Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin", Am J Pathol, 151, pp.665~670 (1997)
31. MacDougall JR, "The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells", Cancer Res, 55, pp.4174~4181 (1995)
32. Hofmann UB, "Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation", Cancer Res, 63, pp.8221~8225 (2003)
33. d'Ortho MP, "Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases", Eur J Biochem, 250, pp.751~757 (1997)
34. Deryugina EI, "Up-regulation of vascular endothelial growth factor by membrane-type 1matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis", Cancer Res, 62, pp.580~588 (2002)
35. Hotary K, "Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3", J Cell Biol, 149, pp.1309~1323 (2000)
36. Iida J, "Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth", J Invest Dermatol, 122, pp.167~176 (2004)
37. Butler GS, "The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study", J Biol Chem, 273, pp.871~880 (1998)
38. Hofmann UB, "Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression", J Pathol, 191, pp.245~256 (2000)
39. Stetler-Stevenson WG, "The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2", Cancer Metastasis Rev, 27, pp.57~66 (2008)
40. Itoh Y, "Homophilic complex formation of MT1-MMP facilitates pro-MMP-2 activation on the cell surface and promotes tumor cell invasion", EMBO J, 20, pp.4782~4793 (2001)
41. Henriet P, "Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation", APMIS, 107, pp.111~119 (1999)
42. Montgomery AM, "Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line", Cancer Res, 54, pp.5467~5473 (1994)
43. Khokha R, "Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1", J Natl Cancer Inst, 86, pp.299~304 (1994)
44. Finan KM, "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2", Lung Cancer, 53, pp.273~284 (2006)

관련 논문AI추천